LivaNova, a market-leading medical technology and innovation company, today announced it is exploring strategic options for its Cardiac Rhythm Management (“CRM”) Business Franchise.
Moleculin Biotech, Inc. today announced it has engaged contract research organization (“CRO”) Bioscience SA (“Bioscience”) to prepare for a proof-of-concept clinical trial in Poland to study its drug candidate WP1220 for the treatment of cutaneous T-cell lymphoma (“CTCL”).
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced positive pooled continuous glucose monitoring (CGM) data from the pivotal Phase 3 inTandem1 and inTandem2 studies of sotagliflozin, an investigational dual SGLT1 and SGLT2 inhibitor.
That could mean more transactions of a similar size in the future for the private equity firm.
The waters are starting to recede from Tropical Storm Harvey, but the work to get Houston and southeast Texas back up to speed is only starting. To help with that, technology communities across Texas are offering aid in the form of free co-working space, discounted rides, a corps of volunteers,
Apollo Endosurgery, Inc. (“Apollo”), a global leader in less invasive medical devices for bariatric and gastrointestinal procedures, today announced CE Mark approval for the ORBERA365 Managed Weight Loss System.
Houston, Texas and Tuebingen, Germany, August 21, 2017 – Immatics, a leading company in the field of cancer immunotherapy, today announced that it has initiated enrollment of patients into a phase I trial of its first adoptive cellular therapy (ACT) IMA101, using its proprietary ACTolog® approach.
Alzeca, which is developing an imaging agent to help doctors detect Alzheimer’s disease at its earliest stages, announced Thursday it has raised $11 million in a Series A round of funding.